Boisse N R, Okamoto M
J Pharmacol Exp Ther. 1978 Mar;204(3):507-13.
This study describes the tolerance characteristics of barbital compared to pentobarbital, the standard drug, during "chronically equivalent" treatment. Barbiturate tolerance was assessed as the increase in dose from the beginning to the end of treatment required to achieve equieffective peak effect. Dispositional tolerance was assessed as a reduction in the elimination half-life of barbiturate from blood. Functional tolerance was assessed as the increase in blood concentration of barbiturate at the time of peak effect. Overall, greater tolerance was developed to pentobarbital than to barbital. For pentobarbital, tolerance was both dispositional and functional; the dispositional tolerance developed rapidly and was almost complete at 1 week. For barbital, tolerance was exclusively functional. A most interesting finding was that functional tolerance to barbital and pentobarbital developed at the same slow rate for chronically equivalent treatment. This finding suggests that functional tolerance development is independent of the particular barbiturate reflecting the adaptability of the central nervous system to chronic depression.
本研究描述了在“长期等效”治疗期间,巴比妥与标准药物戊巴比妥相比的耐受性特征。巴比妥类药物耐受性通过从治疗开始到结束达到等效峰值效应所需的剂量增加来评估。处置耐受性通过巴比妥从血液中消除半衰期的缩短来评估。功能耐受性通过峰值效应时巴比妥血液浓度的增加来评估。总体而言,对戊巴比妥产生的耐受性比对巴比妥更强。对于戊巴比妥,耐受性既有处置性的也有功能性的;处置耐受性发展迅速,在1周时几乎完全形成。对于巴比妥,耐受性仅为功能性的。一个非常有趣的发现是,在长期等效治疗中,对巴比妥和戊巴比妥的功能耐受性以相同的缓慢速度发展。这一发现表明,功能耐受性的发展与特定的巴比妥类药物无关,反映了中枢神经系统对慢性抑制的适应性。